DMD and Duchenne muscular dystrophy: For example, gene therapies were initially intended to bypass the need for repeated doses of existing ASO treatments and were thought to be applicable for almost all DMD patients, but instead led to the implementation of exclusion criteria following several immune reactions against the expressed foreign micro-dystrophin proteins [53,93,94].